
News|Slideshows|December 13, 2023
Two Vaccines Against RSV in Older Adults Approved One Month Apart: It Happened in 2023
Author(s)Grace Halsey
Advertisement
The seasonal respiratory syncytial virus, which claims between 6000 and 10 000 older adult lives each year, will now face significant barriers to spread in this vulnerable population the US.
The short slide show that follows provides snapshots of the headline news stories posted on Patient Care® in 2023 that traced the clinical trials and approval process for GKS's RSVPreF3 (Arexvy) and Pfizer's RSVPreF (Abrysvo).
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
2
FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option
3
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
4
Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management
5

















































































































































